Premium
A phase I trial of ifosfamide and paclitaxel with granulocyte‐colony stimulating factor in the treatment of patients with refractory solid tumors
Author(s) -
Bunnell Craig A.,
Thompson Lynn,
Buswell Lori,
Berkowitz Ross,
Muto Michael,
Sheets Ellen,
Shulman Lawrence N.
Publication year - 1998
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19980201)82:3<561::aid-cncr19>3.0.co;2-#
Subject(s) - medicine , ifosfamide , paclitaxel , refractory (planetary science) , granulocyte colony stimulating factor , granulocyte , clinical trial , chemotherapy , oncology , surgery , physics , etoposide , astrobiology
BACKGROUND Ifosfamide and paclitaxel are antineoplastic agents with broad activity and with different mechanisms of action. A Phase I trial was conducted to determine the maximum tolerated dose and associated toxicities of these agents when used in combination. METHODS Patients with refractory, incurable solid tumors were entered on a 5‐step Phase I trial of ifosfamide, given in doses of 2‐3 g/m 2 intravenous (i.v.) bolus for 3 days with mesna support, and paclitaxel, given in doses of 135‐190 g/m 2 i.v. by continuous infusion over 24 hours. Paclitaxel was given after the first dose of ifosfamide on Day 1. RESULTS Twenty‐three patients were treated, and the maximum tolerated dose was the highest planned dose level of the trial: ifosfamide, 3 g/m 2 /day i.v. for 3 days, and paclitaxel, 190 mg/m 2 i.v. over 24 hours. Hematologic toxicity was not dose‐limiting, and although neutropenia occurred, it was brief (median, 2‐4 days) and resulted in hospitalization for neutropenia and fever in only 7 of 111 courses of therapy. For patients treated at the highest dose level, only 1 of 50 courses of therapy resulted in hospitalization for neutropenia and fever. Nonhematologic toxicity also was not severe and no significant neuropathy occurred. Although patients entered into the study were heavily pretreated, responses were observed, particularly in patients with breast or ovarian carcinoma. CONCLUSIONS Ifosfamide and paclitaxel can be administered safely in the doses used in this study and there are indications of significant antitumor effect. Further studies are necessary to explore the antineoplastic activity of this regimen, particularly for patients with breast and ovarian carcinoma. Cancer 1998;82:561‐6. © 1998 American Cancer Society.